{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:15:55Z","timestamp":1794917755882,"version":"4.9.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.intimp.2022.108795","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T19:37:12Z","timestamp":1651001832000},"page":"108795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["3, 3\u2032- diindolylmethane hinders IL-17A\/IL-17RA interaction and mitigates imiquimod-induced psoriasiform in mice"],"prefix":"10.1016","volume":"109","author":[{"given":"Manupati","family":"Srikanth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahaboobkhan","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2022.108795_b0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/JLB.5MR0120-439R","article-title":"Keratinocyte: A trigger or an executor of psoriasis?","volume":"108","author":"Ni","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.108795_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/8065147","article-title":"Association of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients","volume":"2020","author":"Aguilar-Flores","year":"2020","journal-title":"Mediators Inflamm."},{"issue":"2","key":"10.1016\/j.intimp.2022.108795_b0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0625.2011.01412.x","article-title":"IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion","volume":"21","author":"Gutowska-Owsiak","year":"2012","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.immuni.2020.06.004","article-title":"Excessive Polyamine Generation in Keratinocytes Promotes Self-RNA Sensing by Dendritic Cells in Psoriasis","volume":"53","author":"Lou","year":"2020","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2022.108795_b0030","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2022.108795_b0035","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108795_b0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/exd.12710","article-title":"Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis","volume":"24","author":"Reich","year":"2020","journal-title":"Exp. Dermatol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108795_b0045","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","article-title":"Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther. Adv. Chronic. Dis."},{"issue":"47","key":"10.1016\/j.intimp.2022.108795_b0055","doi-asserted-by":"crossref","first-page":"35603","DOI":"10.1074\/jbc.C600256200","article-title":"Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor","volume":"281","author":"Chang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: a review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2022.108795_b0065","doi-asserted-by":"crossref","unstructured":"K. Miyoshi, M. Takaishi, K. Nakajima, M. Ikeda, T. Kanda, M. Tarutani, T. Iiyama, N. Asao, J. DiGiovanni, S. Sano, Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor, J. Invest. Dermatol 131(1) (2011) 108-17.","DOI":"10.1038\/jid.2010.255"},{"issue":"12","key":"10.1016\/j.intimp.2022.108795_b0070","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/jid.2011.222","article-title":"IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms","volume":"131","author":"Shi","year":"2011","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108795_b0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.intimp.2014.01.027","article-title":"Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2\/STAT3 pathway","volume":"19","author":"Xu","year":"2014","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108795_b0080","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1111\/j.1365-2230.2008.02991.x","article-title":"Complete remission of psoriasis following bevacizumab therapy for colon cancer","volume":"34","author":"Akman","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108795_b0085","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2020.10.094","article-title":"CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health","volume":"84","author":"Elnabawi","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0090","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/jid.2012.260","article-title":"CCR6 is required for epidermal trafficking of \u03b3\u03b4-T cells in an IL-23-induced model of psoriasiform dermatitis","volume":"133","author":"Mabuchi","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jdermsci.2017.05.018","article-title":"Cyr61\/CCN1 induces CCL20 production by keratinocyte via activating p38 and JNK\/AP-1 pathway in psoriasis","volume":"88","author":"Li","year":"2017","journal-title":"J. Dermatol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2022.108795_b0100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/jdv.13564","article-title":"High mobility group box 1 is increased in the sera of psoriatic patients with disease progression","volume":"30","author":"Bergmann","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108795_b0105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"2","key":"10.1016\/j.intimp.2022.108795_b0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/tx00026a007","article-title":"Oligomerization of indole-3-carbinol in aqueous acid","volume":"5","author":"Grose","year":"1992","journal-title":"Chem. Res. Toxicol."},{"issue":"46","key":"10.1016\/j.intimp.2022.108795_b0115","doi-asserted-by":"crossref","first-page":"18650","DOI":"10.1073\/pnas.1308206110","article-title":"DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism","volume":"110","author":"Fan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2010.02.014","article-title":"3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants","volume":"295","author":"Rahimi","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2022.108795_b0125","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02483624."},{"issue":"5","key":"10.1016\/j.intimp.2022.108795_b0130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.bcp.2009.10.010","article-title":"3,3'-Diindolylmethane attenuates experimental arthritis and osteoclastogenesis","volume":"79","author":"Dong","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2022.108795_b0135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.molimm.2020.11.013","article-title":"3, 3'-Diindolylmethane alleviates acute atopic dermatitis by regulating T cell differentiation in a mouse model","volume":"130","author":"Wu","year":"2021","journal-title":"Mol. Immunol."},{"issue":"467","key":"10.1016\/j.intimp.2022.108795_b0140","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaf8823","article-title":"The flavonoid cyanidin blocks binding of the cytokine interleukin-17A to the IL-17RA subunit to alleviate inflammation in vivo","volume":"10","author":"Liu","year":"2017","journal-title":"Sci. Signal."},{"key":"10.1016\/j.intimp.2022.108795_b0145","doi-asserted-by":"crossref","first-page":"107229","DOI":"10.1016\/j.intimp.2020.107229","article-title":"Indirubin attenuates IL-17A-induced CCL20 expression and production in keratinocytes through repressing TAK1 signaling pathway","volume":"94","author":"Zhao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2022.108795_b0150","doi-asserted-by":"crossref","unstructured":"T.N. Kj\u00e6r, K. Thorsen, N. Jessen, K. Stenderup, S.B. Pedersen, Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice, PloS One 10 (5) (2015): e0126599.","DOI":"10.1371\/journal.pone.0126599"},{"issue":"7","key":"10.1016\/j.intimp.2022.108795_b0155","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.intimp.2022.108795_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220868","article-title":"Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response","volume":"14","author":"Sawyer","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2022.108795_b0165","first-page":"12","article-title":"RPL22 Overexpression Promotes Psoriasis-Like Lesion by Inducing Keratinocytes Abnormal Biological Behavior","author":"Zeng","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/etm.2020.9480","article-title":"IL-17 promotes proliferation, inflammation and inhibits apoptosis of HaCaT cells via interacting with the TRAF3 interacting protein 2","volume":"21","author":"Zhang","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0175","first-page":"1","article-title":"CCN1 promotes IL-1\u03b2 production in keratinocytes by activating p38 MAPK signaling in psoriasis","volume":"7","author":"Sun","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.108795_b0180","doi-asserted-by":"crossref","unstructured":"B. Homey, M.C. Dieu-Nosjean, A. Wiesenborn, C. Massacrier, J.J. Pin, E. Oldham, D. Catron, M.E. Buchanan, A. M\u00fcller, R. deWaal Malefyt, G. Deng, R. Orozco, T. Ruzicka, P. Lehmann, S. Lebecque, C. Caux, A. Zlotnik, Up-regulation of macrophage inflammatory protein-3 alpha\/CCL20 and CC chemokine receptor 6 in psoriasis, J. Immunol. 164 (12) (2000) 6621-32.","DOI":"10.4049\/jimmunol.164.12.6621"},{"issue":"1","key":"10.1016\/j.intimp.2022.108795_b0185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4062\/biomolther.2014.102","article-title":"Keratinocytic vascular endothelial growth factor as a novel biomarker for pathological skin condition","volume":"23","author":"Bae","year":"2015","journal-title":"Biomol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2022.108795_b0190","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/path.4848","article-title":"Pro-inflammatory effect of high-mobility group protein B1 on keratinocytes: an autocrine mechanism underlying psoriasis development","volume":"24","author":"Zhang","year":"2017","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108795_b0195","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjd.20090","article-title":"Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways","volume":"185","author":"Tollenaere","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2022.108795_b0200","doi-asserted-by":"crossref","unstructured":"M. Kira, S. Sano, S. Takagi, K. Yoshikawa, J. Takeda, S. Itami, STAT3 deficiency in keratinocytes leads to compromised cell migration through hyperphosphorylation of p130(cas), J. Biol. Chem. 277 (15) (2002) 12931-6.","DOI":"10.1074\/jbc.M110795200"},{"key":"10.1016\/j.intimp.2022.108795_b0205","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis","author":"Hsu","year":"2014","journal-title":"J Immunol. Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200279X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200279X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:38:51Z","timestamp":1761586731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692200279X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":41,"alternative-id":["S156757692200279X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108795","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3, 3\u2032- diindolylmethane hinders IL-17A\/IL-17RA interaction and mitigates imiquimod-induced psoriasiform in mice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108795"}}